MOTS-c is in the July 2026 FDA peptide review queue.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration
Refresh regulatory context before adding broader claim coverage.
Mitochondrial peptide
MOTS-c
MOTS-c is a peptide topic commonly associated with metabolic and longevity discussions online. This starter page keeps the topic in the review queue without endorsing those claims.
Regulatory watch
Last reviewed 2026-06-30
Next review 2026-07-24
Evidence snapshot
Map claims to sources before publishing broader explanatory copy.
Scheduled for FDA advisory committee discussion in July 2026.
Likely to attract longevity-oriented claims that require careful source labeling.
High priority for a post-meeting refresh.
Tracked claims
Sources on this page
Source records are stored in the repo and linked from each claim.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
Certain bulk drug substances for use in compounding may present significant safety risks
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.